Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal

Fineline Cube Dec 14, 2025
Company Deals

InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program

Fineline Cube Dec 14, 2025
Company Deals

Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery

Fineline Cube Dec 13, 2025
Company Deals

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs

Fineline Cube Dec 13, 2025
Company Deals

B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline

Fineline Cube Dec 13, 2025
Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025
Company Drug

Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial

Fineline Cube Dec 14, 2025
Company Drug

Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment

Fineline Cube Dec 14, 2025
Company Drug

Fidia Farmaceutici’s Hyalubrix 60 Shows Promise in Treating Arthropathy at Hainan Hospital

Fineline Cube Jul 25, 2022

Italy-based Fidia Farmaceutici S.p.A announced that its Hyalubrix 60, a prefilled syringe with sodium hyaluronate...

Company Deals

Linno Pharmaceuticals Raises USD 14.78M for Blood-Brain Barrier Drug Delivery Tech

Fineline Cube Jul 22, 2022

Shanghai-based rare disease specialist Linno Pharmaceuticals Inc. has reportedly raised close to RMB 100 million...

Company Deals

Frontier Biotech Raises USD 51.4M to Advance COVID-19 Drug FB2001

Fineline Cube Jul 22, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) announced plans to raise RMB 270 million (USD 51.4...

Company Deals

Curatia Medical Raises Tens of Millions in Funding Co-led by Hidea Investment

Fineline Cube Jul 22, 2022

Curatia Medical Ltd, a vascular interventional therapy developer with operations in Silicon Valley, California, and...

Company Deals

Novaremed AG Licenses NRD.E1 to NeuroFront for Greater China Development

Fineline Cube Jul 22, 2022

Switzerland-based Novaremed AG has entered into a licensing agreement with China’s NeuroFront (Shanghai) Co., Ltd,...

Drug

Ascentage Pharma’s Olverembatinib Receives Health Canada Approval for Phase Ib Study

Fineline Cube Jul 22, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) announced that it has received approval from Health Canada to...

Company Drug

Junshi Biosciences’ Toripalimab Receives EC Orphan Drug Designation for NPC

Fineline Cube Jul 22, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that its PD-1 inhibitor Toripalimab (trade name:...

Company Deals

Yifeng Pharmacy Chain to Establish New Company with Tangshan Deshuntang

Fineline Cube Jul 22, 2022

China-based Yifeng Pharmacy Chain Co., Ltd (SHA: 603939) announced that its subsidiary, Shijiazhuang Xinxing Pharmacy...

Company Drug

Ji Xing Pharmaceuticals Enrolls First Patient in OC-01 Phase III Study for Dry Eye

Fineline Cube Jul 22, 2022

Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, announced that the first patient has been...

Company Drug

Gan & Lee Pharmaceuticals Doses First Patient in GZR18 Phase II Study for Diabetes and Obesity

Fineline Cube Jul 22, 2022

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...

Drug

Sinopep-Allsino Biopharm’s SPN0103-009 Receives NMPA Approval for Diabetes and Obesity Clinical Study

Fineline Cube Jul 22, 2022

China-based Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd announced that it has received approval from the National...

Drug

Lepu Biopharma’s Pucotenlimab Receives Conditional NMPA Approval for MSI-H/dMMR Tumors

Fineline Cube Jul 22, 2022

The National Medical Products Administration (NMPA) has granted conditional market approval to Lepu Biopharma Co.,...

Company Deals

Fosun Pharmaceutical to Raise USD 662M via Share Issue for Drug Development and API Base

Fineline Cube Jul 22, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced plans to issue...

Company Drug

Tris Pharma and Pediatrix’s Methylphenidate Tablet, Ipsen’s Triptorelin Injection Awarded Priority Review by CDE

Fineline Cube Jul 22, 2022

The Center for Drug Evaluation (CDE) website shows that US-based Tris Pharma and Pediatrix Therapeutics’...

Company

Roche Posts 5% H1 Sales Growth, Led by New Drugs and Immunodiagnostics

Fineline Cube Jul 22, 2022

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) reported a 5% year-on-year (YOY) increase in...

Company Drug

InnoCare’s Tafasitamab Receives First Prescription in China’s Bo’Ao Lecheng Pilot Zone

Fineline Cube Jul 22, 2022

China-based InnoCare (HKG: 9969) announced that the first prescription for its pipeline candidate tafasitamab (trade...

Company Deals

Harbin Gloria Partners with Genolmmune on PD-1 and Neoantigen Therapy for NSCLC

Fineline Cube Jul 21, 2022

China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has partnered with Genolmmune Therapeutics Biotechnology Co.,...

Company Deals

MAXVAX Biotech Raises RMB500M in Series B to Advance Vaccine Pipelines

Fineline Cube Jul 21, 2022

MAXVAX Biotechnology LLC, a Chengdu-based vaccine and novel adjuvant developer, reportedly raised RMB500 million ($73.9...

Company Drug

Livzon’s V-01 and V-01D-351 Vaccines Show Strong Safety, Immunity as COVID Boosters

Fineline Cube Jul 21, 2022

China-based Livzon Pharmaceutical Group (HKG: 1513) released clinical data for its recombinant novel coronavirus fusion...

Drug

CANbridge Pharmaceuticals Doses First Patient in CAN103 Gaucher Disease Trial

Fineline Cube Jul 21, 2022

China-based rare disease firm CANbridge Pharmaceuticals announced the dosing of the first patient in a...

Posts pagination

1 … 577 578 579 … 597

Recent updates

  • Peijia Medical Wins NMPA Approval for TaurusTrio TAV, First Transfemoral System for Aortic Regurgitation
  • Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal
  • Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial
  • Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment
  • InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Peijia Medical Wins NMPA Approval for TaurusTrio TAV, First Transfemoral System for Aortic Regurgitation

Company Deals

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal

Company Drug

Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial

Company Drug

Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.